aStudy design1: Patients underwent a 4-week open-label titration phase in which treatment was initiated at 1500 mg and titrated by 750 mg/day at 1-week intervals up to 3000 mg/day to achieve control (patients received an average of 3 tablets/day). In those patients who responded to FOSRENOL® (phosphorus <5.5 mg/dL), open-label treatment was continued for an additional 4 weeks with their final titrated dose (1500 mg, 2250 mg, 3000 mg). Patients then entered a 4-month open-label extension phase for a total treatment duration of 24 weeks. The standard deviations for all the data points reported above were ±1.45, ±1.58, ±1.39, ±1.31, ±0.88, ±1.23, ±1.45, ±1.44, ±1.22, ±1.47, ±1.41, ±1.46, and ±1.43, respectively. Change from baseline at all time points was statistically significant (P<.0001).
bDosing based on 3 meals per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.
cBaseline data were not available for 1 patient at the time of assessment.
- Patients taking FOSRENOL® attained K/DOQI phosphorus levels within 2 weeks
- K/DOQI phosphorus levels were maintained throughout the 24-week study
- In a separate clinical trial, phosphorus levels* were maintained for 3 years in nearly 70% of patients (n=46)3
*Phosphorus control was defined as <5.6 mg/dL.
